Nuvectis Pharma, Inc. Income Statement

Income Statement Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Gross Profit -1.18M-0.84M-0.61M
Expense - Real Estate 1.18M0.84M0.61M
Operating items
Research & Development 9.54M13.23M15.38M12.92M
Wages, Salaries and Other 2.57M2.38M3.46M3.46M
Selling, General & Administrative 3.35M6.01M7.52M6.93M
Restructuring Costs 0.36M0.42M0.55M0.36M
Operating Expenses 13.26M19.66M23.45M20.21M
Operating Income -12.89M-19.23M-22.90M-19.85M
EBIT -12.89M-19.23M-22.90M-19.85M
Non-operating items
Interest & Investment Income 0.00M0.15M0.64M0.85M
Net income details
EBT -12.89M-19.09M-22.26M-19.00M
Profit After Tax -12.89M-19.09M-22.26M-19.00M
Income from Continuing Operations -12.89M-19.09M-22.26M-19.00M
Consolidated Net Income -12.89M-19.09M-22.26M-19.00M
Income towards Parent Company -12.89M-19.09M-22.26M-19.00M
Net Income towards Common Stockholders -12.89M-19.09M-22.26M-19.00M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 11.60M14.64M17.33M19.32M
EBITDA -12.89M-19.23M-22.90M-19.85M